Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O00487
UPID:
PSDE_HUMAN
Alternative names:
26S proteasome regulatory subunit RPN11; 26S proteasome-associated PAD1 homolog 1
Alternative UPACC:
O00487; B3KNW2; O00176
Background:
The 26S proteasome non-ATPase regulatory subunit 14, also known as PSMD14, plays a crucial role in cellular protein homeostasis. It is a component of the 26S proteasome, a complex essential for the ATP-dependent degradation of ubiquitinated proteins. PSMD14's function in cleaving 'Lys-63'-linked polyubiquitin chains is vital for processes such as cell cycle progression, apoptosis, and DNA damage repair.
Therapeutic significance:
Understanding the role of 26S proteasome non-ATPase regulatory subunit 14 could open doors to potential therapeutic strategies.